TL;DR
Targeting the IGF2BP3-CENPA axis may provide a novel therapeutic strategy to overcome chemoresistance in BUC.
It is identified that RBM15/IFI6 axis is a novel m6A-dependent pathway driving BLCA progression, offering a potential therapeutic target for BLCA.
Background: Hepatocellular carcinoma (HCC) is among the most lethal malignancies, and its immunosuppressive microenvironment limits the efficacy of current therapies. The integrin β1 (ITGB1)-CDC42-p21-activated kinase 1 (PAK1) axis is an established driver of HCC progression; however, the role of copine 8 (CPNE8), a ca...
The functional role of ACOT7 was examined using an integrated approach, combining analysis of clinical datasets with in vitro and in vivo experiments, and MYC-associated regulation and changes in total AKT and p-MDM2 levels suggest a potential connection between ACOT7 and growth-related signaling.
The results suggest that the pro-tumorigenic effects of XPR1 in thyroid carcinoma cells, manifested by increased cell growth, motility, invasiveness, and reduced susceptibility to apoptosis, may be partly associated with NF-κB signaling.
Clinically, these findings identify the METTL1/USP48/LCN2 pathway as a potential therapeutic target for cSCC and elucidated a novel oncogenic axis in cSCC, wherein METTL1 stabilized USP48 mRNA through m7G methylation modification, and USP48 in turn deubiquitinated and stabilized LCN2 protein.
It is revealed that IGF2BP3 drives HCC malignancy by establishing a reciprocal interaction between tumor cells and macrophages via the CSF1/CSF1R signaling pathway, highlighting that therapeutic targeting of this axis may disrupt tumor-macrophage crosstalk and improve therapeutic efficacy.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
